Multiple large cell neuroendocrine carcinomas in the rectum and descending colon presented with liver metastasis: A case report

Introduction Metastasis to the gastrointestinal tract from lung cancer is very uncommon and is often asymptomatic. Although small bowel metastasis may commonly occur, metastases to the stomach and colon are uncommon. Case report In this paper, we present a previously healthy 57-year-old male patient, a 60-packet per year smoker, who was taken to the emergency room with complaints of increasing abdominal pain, rectal bleeding, weight loss, and dyspnea for the last three months. Endoscopic examination revealed polypoid lesions in the duodenum and the descending colon. We diagnosed neuroendocrine small-cell lung cancer based on histopathological and immunohistochemical staining. Management and outcome: A cisplatin (d1, 60 mg/m2/day)–etoposide (d1 to d3, 120 mg/m2/day) regimen was given every three weeks as palliative chemotherapy. After the three course of chemotherapy, the lung radiograph showed a decline in hilar expansion and there was no pleural effusion. Then, he died of acute respiratory failure two weeks after radiotherapy of brain. Discussion Gastrointestinal tract metastasis of lung cancer is recognized synchronously with or rarely before diagnosis. It is generally recognized after the diagnosis of lung cancer. These patients often have other concurrent body metastases. Prognosis is poor, and survival expectation is short. The most common metastases to the gastrointestinal tract are squamous and large cell lung cancer metastases. Our aim is to emphasize the importance of immunohistochemical examination for masses in the gastrointestinal tract and to present this rare case of synchronous duodenal and colonic metastases of small-cell lung cancer.

Download Full-text

Combined large-cell neuroendocrine carcinoma and endometrioid adenocarcinoma of the endometrium: A case report

10.26226/morressier.596dfd57d462b8029238785a ◽

2017 ◽

Author(s):

Neli Basheska

Keyword(s):

Case Report ◽

Neuroendocrine Carcinoma ◽

Large Cell ◽

Large Cell Neuroendocrine Carcinoma ◽

Endometrioid Adenocarcinoma

Download Full-text

Hydradenocarcinoma with liver metastasis: a case report

Academic Journal of Second Military Medical University ◽

10.3724/sp.j.1008.2009.01051 ◽

2009 ◽

Vol 29 (9) ◽

pp. 1051-1051

Author(s):

Li JIANG ◽

Ping LI

Keyword(s):

Case Report ◽

Liver Metastasis

Download Full-text

Mixed Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) of the Ovary Arising from Endometriosis: Molecular Pathology Analysis in Support of a Pathogenetic Paradigm

Endocrine Pathology ◽

10.1007/s12022-021-09689-8 ◽

2021 ◽

Author(s):

Roberta Maragliano ◽

Laura Libera ◽

Ileana Carnevali ◽

Valeria Pensotti ◽

Giovanna De Vecchi ◽

...

Keyword(s):

Large Cell ◽

Neuroendocrine Neoplasm ◽

Molecular Profile ◽

Neuroendocrine Neoplasms ◽

Fish Analysis ◽

Sequencing Analysis ◽

Endometrioid Carcinoma ◽

Preneoplastic Lesions ◽

Ovarian Endometriosis ◽

Neuroendocrine Carcinomas

AbstractPrimary ovarian neuroendocrine neoplasms (Ov-NENs) are infrequent and mainly represented by well-differentiated forms (neuroendocrine tumors — NETs — or carcinoids). Poorly differentiated neuroendocrine carcinomas (Ov-NECs) are exceedingly rare and only few cases have been reported in the literature. A subset of Ov-NECs are admixed with non-neuroendocrine carcinomas, as it occurs in other female genital organs, as well (mostly endometrium and uterine cervix), and may be assimilated to mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) described in digestive and extra-digestive sites. Here, we present a case of large cell Ov-NEC admixed with an endometrioid carcinoma of the ovary, arising in the context of ovarian endometriosis, associated with a uterine endometrial atypical hyperplasia (EAH). We performed targeted next-generation sequencing analysis, along with a comprehensive immunohistochemical study and FISH analysis for TP53 locus, separately on the four morphologically distinct lesions (Ov-NEC, endometrioid carcinoma, endometriosis, and EAH). The results of our study identified molecular alterations of cancer-related genes (PIK3CA, CTNNB1, TP53, RB1, ARID1A, and p16), which were present with an increasing gradient from preneoplastic lesions to malignant proliferations, both neuroendocrine and non-neuroendocrine components. In conclusion, our findings underscored that the two neoplastic components of this Ov-MiNEN share a substantially identical molecular profile and they progress from a preexisting ovarian endometriotic lesion, in a patient with a coexisting preneoplastic proliferation of the endometrium, genotypically and phenotypically related to the ovarian neoplasm. Moreover, this study supports the inclusion of MiNEN in the spectrum ovarian and, possibly, of all gynecological NENs, among which they are currently not classified.

Download Full-text

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

npj Precision Oncology ◽

10.1038/s41698-021-00214-y ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Aaron S. Mansfield ◽

David S. Hong ◽

Christine L. Hann ◽

Anna F. Farago ◽

Himisha Beltran ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Medullary Thyroid Cancer ◽

Large Cell ◽

Antibody Drug Conjugate ◽

Medullary Thyroid ◽

Neuroendocrine Prostate Cancer ◽

Grade 3 ◽

Recommended Phase Ii Dose ◽

Neuroendocrine Carcinomas

AbstractDelta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15/145 patients (10%) treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.

Download Full-text

Right trisectionectomy for liver metastasis of granulosa cell tumor: a case report and literature review

Surgical Case Reports ◽

10.1186/s40792-020-00880-3 ◽

2020 ◽

Vol 6 (1) ◽

Author(s):

Itsuki Koganezawa ◽

Koichi Tomita ◽

Masashi Nakagawa ◽

Yosuke Ozawa ◽

Toshimichi Kobayashi ◽

...

Keyword(s):

Case Report ◽

Liver Metastasis ◽

Literature Review ◽

Granulosa Cell ◽

Granulosa Cell Tumor ◽

Cell Tumor

Download Full-text

Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder

Signal Transduction and Targeted Therapy ◽

10.1038/s41392-020-00412-3 ◽

2021 ◽

Vol 6 (1) ◽

Author(s):

Fatao Liu ◽

Yongsheng Li ◽

Dongjian Ying ◽

Shimei Qiu ◽

Yong He ◽

...

Keyword(s):

Gene Mutations ◽

Large Cell ◽

Molecular Signatures ◽

Single Nucleotide Variants ◽

Oncogenic Signaling ◽

Single Nucleotide ◽

Whole Exome ◽

Deadly Disease ◽

Oncogenic Signaling Pathways ◽

Neuroendocrine Carcinomas

AbstractNeuroendocrine carcinoma (NEC) of the gallbladder (GB-NEC) is a rare but extremely malignant subtype of gallbladder cancer (GBC). The genetic and molecular signatures of GB-NEC are poorly understood; thus, molecular targeting is currently unavailable. In the present study, we applied whole-exome sequencing (WES) technology to detect gene mutations and predicted somatic single-nucleotide variants (SNVs) in 15 cases of GB-NEC and 22 cases of general GBC. In 15 GB-NECs, the C > T mutation was predominant among the 6 types of SNVs. TP53 showed the highest mutation frequency (73%, 11/15). Compared with neuroendocrine carcinomas of other organs, significantly mutated genes (SMGs) in GB-NECs were more similar to those in pulmonary large-cell neuroendocrine carcinomas (LCNECs), with driver roles for TP53 and RB1. In the COSMIC database of cancer-related genes, 211 genes were mutated. Strikingly, RB1 (4/15, 27%) and NAB2 (3/15, 20%) mutations were found specifically in GB-NECs; in contrast, mutations in 29 genes, including ERBB2 and ERBB3, were identified exclusively in GBC. Mutations in RB1 and NAB2 were significantly related to downregulation of the RB1 and NAB2 proteins, respectively, according to immunohistochemical (IHC) data (p values = 0.0453 and 0.0303). Clinically actionable genes indicated 23 mutated genes, including ALK, BRCA1, and BRCA2. In addition, potential somatic SNVs predicted by ISOWN and SomVarIUS constituted 6 primary COSMIC mutation signatures (1, 3, 30, 6, 7, and 13) in GB-NEC. Genes carrying somatic SNVs were enriched mainly in oncogenic signaling pathways involving the Notch, WNT, Hippo, and RTK-RAS pathways. In summary, we have systematically identified the mutation landscape of GB-NEC, and these findings may provide mechanistic insights into the specific pathogenesis of this deadly disease.

Download Full-text